Navigation Links
Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
Date:7/11/2008

SAN FRANCISCO, July 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of CD-NP in patients with heart failure. Key assessments include measurement of pulmonary capillary wedge pressure (PCWP), plasma cGMP, a secondary messenger of the target receptor, blood pressure, heart rate, serum potassium and renal function. Nile expects up to 30 heart failure patients will be enrolled in the trial.

Results from the Phase Ia study in 22 healthy volunteers were consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, preserved renal function, increased natriuresis and diuresis with minimal effect on mean arterial pressure. In parallel with the Phase IIa study, Nile is completing its Phase Ib study of CD-NP. The primary objectives of the Phase Ib study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Results from both the Phase Ib and Phase IIa trials are expected to be available in 2008.

"We are pleased to have reached this important corporate milestone and to be able to begin this Phase II trial of CD-NP in heart failure patients," said Peter Strumph, Chief Executive Officer of Nile. "We look forward to rapidly enrolling this Phase II trial and to further investigating the clinical e
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Silence Therapeutics Announces Board Changes
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
5. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
6. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
7. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
8. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
9. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
10. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
11. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ... company, announced today that it has completed integration ... solution for Plastic Surgery and Dermatology practices. ... more value to healthcare practices using Nextech," stated ... eRelevance Corporation. "Using information from the EMR we ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... WARREN, N.J., Jan. 17, 2012 Roka Bioscience announced ... AOAC Performance Tested Method(SM) certification from the ... was conducted by Silliker, Inc., as part of the ... The Roka Listeria Detection Assay runs on the ...
... Positron Corporation (OTCBB: POSC), a leading molecular imaging company ... to announce the acquisition of Manhattan Isotope Technology, LLC ... operations and retained all employees of MIT. In exchange, ... and earn-out consideration of $3,500,000 based on 20 percent ...
Cached Medicine Technology:Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay 2Positron Finalizes Acquisition of Manhattan Isotope Technology, LLC 2Positron Finalizes Acquisition of Manhattan Isotope Technology, LLC 3
(Date:8/22/2014)... (PRWEB) August 23, 2014 2014 ... is a professional and in-depth research report on ... Glucose Meter information, including Glucose Meter definition, classification, ... industry overview. This research covers the international market ... industry analysis covering macroeconomic environment & economic situation ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
(Date:8/22/2014)... Sacramento, CA (PRWEB) August 22, 2014 Buying ... to an adult who is unsure about available coverage types ... now providing principal life insurance policy pricing to the public ... The use of this tool is free and is expected ... are available to the public throughout the U.S. The system ...
(Date:8/22/2014)... 22, 2014 Millennium Treatment Group has recently ... a high level of drug use among teenagers. The treatment ... drug addiction and work to minimize drug abuse. , America ... and drug addiction in history. According to the National ... million Americans aged 12 or older—or 9.2 percent of the ...
Breaking Medicine News(10 mins):Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... a 27% Increase in Revenues, DALLAS, Oct. 30 ... of Internet-based claims,processing solutions for the healthcare industry, today ... ended September 30, 2008., "We are pleased to ... Don Crosbie, chief executive officer of Claimsnet.,"The increase in ...
... Philips,Electronics (NYSE: PHG , AEX: PHI) today ... offer quick relief from seasonal mood-related,problems. With the ... affected,by the increased darkness and experience what is ... blues may include lethargy, lowered mood, problems,sleeping, carbohydrate ...
... Mylan Inc. (NYSE: MYL ),today announced that ... company has declared its quarterly dividend of $16.25 per,share ... a liquidation,preference of $1,000.00 per share) payable on Nov. ... of Oct. 31, 2008., Mylan Inc., which provides ...
... VIRGINIA BEACH, Va., Oct. 30, 2008 AMERIGROUP,Corporation (NYSE: ... in the,17th Annual Credit Suisse Healthcare Conference on November ... Company,s presentation, which begins Thursday,November 13 at 4:00 p.m. ... http://www.amerigroupcorp.com, on the investors, page. A replay will,be ...
... age of disease onset and nerve cell death , , ... genes may be linked to the most common form ... team, from Massachusetts General Hospital-MassGeneral Institute for Neurological Disease ... families with a history of the devastating neurological disorder. ...
... Oct. 30 WellPoint,s commercial marketing,team was awarded ... Association,(DMA) for its innovative campaign, "Ecosphere -- Simple ... International ECHO Awards competition is the only international,award ... creativity,strategy and response results., WellPoint,s campaign, conducted ...
Cached Medicine News:Health News:Claimsnet.com Reports Third Quarter 2008 Results 2Health News:Claimsnet.com Reports Third Quarter 2008 Results 3Health News:Philips Introduces New, Advanced Light Therapy Device to Offer Quick Relief from Winter Blues 2Health News:Philips Introduces New, Advanced Light Therapy Device to Offer Quick Relief from Winter Blues 3Health News:Scientists Spot 4 New Alzheimer's Genes 2Health News:WellPoint Awarded Prestigious International Marketing Award 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: